- Home
- Publications
- Publication Search
- Publication Details
Title
Advances in Combining Radiation and Immunotherapy in Breast Cancer
Authors
Keywords
Cancer immunotherapy, Metastatic breast cancer, Triple-negative breast cancer, Tumor microenvironment, Radiation oncology
Journal
Clinical Breast Cancer
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-03-19
DOI
10.1016/j.clbc.2021.03.007
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination
- (2021) Jiali Yu et al. NATURE MEDICINE
- Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control
- (2021) Claire Lhuillier et al. JOURNAL OF CLINICAL INVESTIGATION
- A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer
- (2020) Romualdo Barroso-Sousa et al. Clinical Breast Cancer
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
- (2020) Stephen A. Jannetti et al. Frontiers in Pharmacology
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
- (2020) Rita Nanda et al. JAMA Oncology
- Optimizing Radiotherapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists
- (2020) Alice Y. Ho et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Effects of Radiation on the Tumor Microenvironment
- (2020) Arta M. Monjazeb et al. SEMINARS IN RADIATION ONCOLOGY
- Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
- (2020) David A. Palma et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiotherapy Cooperates with IL15 to Induce Antitumor Immune Responses
- (2020) Karsten A. Pilones et al. Cancer Immunology Research
- Improved survival associated with local tumor response following multi-site radiotherapy and pembrolizumab: secondary analysis of a phase I trial
- (2020) Jason J. Luke et al. CLINICAL CANCER RESEARCH
- Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials
- (2020) Willemijn S M E Theelen et al. Lancet Respiratory Medicine
- Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma
- (2020) Hampartsoum B Barsoumian et al. Journal for ImmunoTherapy of Cancer
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer
- (2020) Eric J. Lehrer et al. JAMA Oncology
- Immunotherapy and targeted therapy combinations in metastatic breast cancer
- (2019) Francisco J Esteva et al. LANCET ONCOLOGY
- Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
- (2019) Leonie Voorwerk et al. NATURE MEDICINE
- Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer
- (2019) Willemijn S. M. E. Theelen et al. JAMA Oncology
- A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple‐negative breast cancer
- (2019) Alice Y. Ho et al. CANCER
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- The Role of TLRs in Anti-cancer Immunity and Tumor Rejection
- (2019) Zuzanna Urban-Wojciuk et al. Frontiers in Immunology
- Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
- (2019) Lorenza Landi et al. Journal for ImmunoTherapy of Cancer
- Immune induction strategies to enhance responses to PD-1 blockade: lessons from the TONIC trial
- (2019) Sandra Demaria et al. Journal for ImmunoTherapy of Cancer
- Ionizing Radiation and Complex DNA Damage: From Prediction to Detection Challenges and Biological Significance
- (2019) Ifigeneia V. Mavragani et al. Cancers
- Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy
- (2018) Ariel E. Marciscano et al. CLINICAL CANCER RESEARCH
- Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
- (2018) Hope S. Rugo et al. CLINICAL CANCER RESEARCH
- Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors
- (2018) Jason J. Luke et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of PD-1 during effector CD8 T cell differentiation
- (2018) Eunseon Ahn et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
- (2018) Leisha A. Emens et al. JAMA Oncology
- Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Radiotherapy induces responses of lung cancer to CTLA-4 blockade
- (2018) Silvia C. Formenti et al. NATURE MEDICINE
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation
- (2018) Zachary S. Buchwald et al. Frontiers in Oncology
- Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
- (2017) Norikazu Masuda et al. NEW ENGLAND JOURNAL OF MEDICINE
- Host STING-dependent MDSC mobilization drives extrinsic radiation resistance
- (2017) Hua Liang et al. Nature Communications
- DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
- (2017) Claire Vanpouille-Box et al. Nature Communications
- Systematic review of case reports on the abscopal effect
- (2016) Yazan Abuodeh et al. CURRENT PROBLEMS IN CANCER
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy
- (2016) Sarah S. Mougalian et al. JAMA Oncology
- Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy
- (2016) Kristina H. Young et al. PLoS One
- TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity
- (2015) Claire Vanpouille-Box et al. CANCER RESEARCH
- Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors
- (2015) J. R. Baird et al. CANCER RESEARCH
- Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial
- (2015) Encouse B Golden et al. LANCET ONCOLOGY
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- Clinical relevance of host immunity in breast cancer: from TILs to the clinic
- (2015) Peter Savas et al. Nature Reviews Clinical Oncology
- T H 2-Polarized CD4 + T Cells and Macrophages Limit Efficacy of Radiotherapy
- (2015) Stephen L. Shiao et al. Cancer Immunology Research
- Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
- (2014) S. J. Dovedi et al. CANCER RESEARCH
- STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
- (2014) Liufu Deng et al. IMMUNITY
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- IFN-γ Mediates the Antitumor Effects of Radiation Therapy in a Murine Colon Tumor
- (2013) Scott A. Gerber et al. AMERICAN JOURNAL OF PATHOLOGY
- Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8+ T cells
- (2013) Joanne Y. H. Lim et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- (2012) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon-Dependent Innate and Adaptive Immunity
- (2011) B. C. Burnette et al. CANCER RESEARCH
- Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody
- (2009) M. Z. Dewan et al. CLINICAL CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started